Sorafenib - Bayer
At a glance
- Drug Originator Onyx Pharmaceuticals; University of Kentucky
- Drug Licenced by Bayer
- Drug Class Amides; Antineoplastics; Benzenesulfonates; Chlorobenzenes; Pyridines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Fms-like tyrosine kinase 3 inhibitors; Mitogen-activated protein kinase inhibitors; Mitogen-activated protein kinase kinase inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Proto oncogene proteins c raf inhibitors; Raf kinase inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
- USA Patent Applicants BAYER HLTHCARE
- USA Patents 11
- NDAs 1
- International Patents 104
- Patent Applications 3,212

Disclaimer